Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects of BRAF Mutations on Non-small Cell Lung Cancer Outcomes and Therapeutic Selection

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

PD-L1 Blueprint Project

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC 2016

The Lung Master Protocol (Lung-MAP)

Changing Landscape of Front-line Immunotherapy

Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small Cell Lung Cancer

Osimertinib: A New Option in Non-Small Cell Lung Cancer - Q&A with David R. Gandara, MD, and Federico Cappuzzo, MD, PhD

Alectinib and ALK-Positive Non-Small Cell Lung Cancer - Q&A with Alice T. Shaw, MD, PhD, and Ranee Mehra, MD

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

Afatinib Outperforms Gefitinib in Advanced Non-Small Cell Lung Cancer

Update on Checkpoint Inhibitors in Lung Cancer